Intermittent preventive treatment in infants (IPTi)
This is an active Deep Dive and we welcome your contributions! If you are currently involved or planning research activities on Intermittent preventive treatment in infants (IPTi) please contact MESA (email@example.com) or add your project to the database.
A WHO Technical Consultation to Review the Role of Drugs in Malaria Prevention for People Living in Endemic Settings took place on October 16 - 17, 2019 [ref]. The meeting discussed malaria chemoprevention including SMC, IPTi and IPTp strategies, with the aim to review the state-of-the-art in the use of chemoprevention to reduce deaths, morbidity and anaemia from malaria, and to reduce malaria transmission, and provide guidance to WHO on priority investments in malaria chemoprevention for people living in endemic settings.
To facilitate the meeting’s work, MESA is compiling a landscape of recent and ongoing research in intermittent preventive treatment in infants (IPTi), a full therapeutic course of antimalarial medicine delivered to infants through routine immunization services, regardless of whether the child is infected with malaria. WHO recommends IPTi with sulfadoxine-pyrimethamine (IPTi-SP) in areas with moderate to high malaria transmission in sub-Saharan Africa that have less than 50% prevalence of pfdhps 540 mutation in the P. falciparum parasite.